Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate: anti-inflammatory or immunosuppressive?

L B van de Putte1, A M Boerbooms, P Barrera

  • 1Department of Rheumatology, University Hospital Nijmegen, The Netherlands.

Clinical and Experimental Rheumatology
|March 1, 1993
PubMed
Summary

Low dose methotrexate effectively treats rheumatoid arthritis by reducing joint inflammation and slowing disease progression. Its mechanism primarily targets the general immune response, not specifically T cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELISA.

Scandinavian journal of rheumatology·2008
Same author

European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA?

Clinical and experimental rheumatology·2002
Same author

Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis.

The American journal of pathology·2001
Same author

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Arthritis and rheumatism·2001
Same author

[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].

Nederlands tijdschrift voor geneeskunde·2001
Same author

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Annals of the rheumatic diseases·2001

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Low-dose methotrexate (MTX) is a cornerstone therapy for rheumatoid arthritis (RA).
  • MTX demonstrates efficacy in suppressing joint inflammation and inhibiting radiographic progression in RA patients.
  • Observed disease-specific side effects suggest MTX possesses immunomodulatory properties.

Purpose of the Study:

  • To elucidate the precise mechanism of action of low-dose methotrexate in rheumatoid arthritis.
  • To investigate whether MTX's immunomodulatory effects are T cell-dependent or involve other immune pathways.

Main Methods:

  • Review of current pharmacological and immunological data on methotrexate's action in RA.
  • Analysis of clinical and experimental evidence regarding MTX's impact on immune cells and inflammatory pathways.

Related Experiment Videos

Main Results:

  • Methotrexate's therapeutic effects in RA are linked to its immunomodulatory actions.
  • Current evidence indicates MTX primarily acts on the non-specific efferent arm of the immuno-inflammatory cascade.
  • The data do not strongly support a direct mechanism of action on T cells.

Conclusions:

  • Low-dose methotrexate's efficacy in rheumatoid arthritis is mediated by its influence on the broader immuno-inflammatory response.
  • The drug's primary mechanism appears to involve downstream inflammatory pathways rather than direct T cell modulation.
  • Further research may clarify the specific targets within the efferent immune arc.